Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Symbiotec Pharmalab IPO launch
Business IPO launch

Symbiotec Pharmalab IPO launch

Analysis based on 8 articles · First reported Aug 19, 2026 · Last updated Aug 24, 2026

Sentiment
40
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The IPO is expected to attract significant investor interest given Symbiotec's strong market position and the active Indian primary market. The listing could boost the company's valuation and provide liquidity to existing investors, while also impacting the pharmaceutical sector's sentiment.

Pharmaceuticals Biotechnology
Event Summary

Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, is launching its initial public offering (IPO) on August 24, 2026, with a price band of Rs 938-988 per share. The IPO aims to raise Rs 1,757 crore, comprising a fresh issue of Rs 150 crore and an offer for sale (OFS) of up to Rs 1,607 crore by existing shareholders. The anchor book opens on August 21, and the issue closes on August 27. Listing on the BSE and NSE is scheduled for September 1. The company plans to use fresh issue proceeds for debt repayment and general corporate purposes. Promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund III will sell shares in the OFS. Symbiotec claims a global leadership position in corticosteroid and steroidal-hormone APIs, with significant market shares. The IPO is managed by JM Financial, Avendus Capital, Motilal Oswal Financial Services, and Nomura Financial, with MUFG Intime India as registrar.

Key Actions
100 Symbiotec Pharmalab launched IPO
80 Rosewood Investments offered shares
75 India Business Excellence Fund III offered shares
70 Satwani Holdings LLP offered shares
60 JM Financial managed IPO Symbiotec Pharmalab
60 Avendus Capital managed IPO Symbiotec Pharmalab
60 Motilal Oswal Financial Services managed IPO Symbiotec Pharmalab
60 Nomura Holdings managed IPO Symbiotec Pharmalab
50 MUFG Intime India registered IPO Symbiotec Pharmalab
Entities Involved
priv
Symbiotec Pharmalab
The company is launching its IPO to raise Rs 1,757 crore, which will strengthen its balance sheet and fund growth. The IPO is a major milestone, providing access to public capital markets.
Importance 100.0 Sentiment 70.0
priv
Rosewood Investments
Rosewood Investments, the largest shareholder, is selling shares worth Rs 988 crore in the OFS, providing an exit opportunity and realizing significant returns.
Importance 70.0 Sentiment 60.0
priv
Satwani Holdings LLP
As the promoter, Satwani Holdings is selling shares worth Rs 144 crore in the OFS, reducing its stake but realizing gains.
Importance 60.0 Sentiment 50.0
priv
India Business Excellence Fund III
The fund is selling shares worth Rs 475 crore in the OFS, partially exiting its investment.
Importance 60.0 Sentiment 55.0
stock
Motilal Oswal Financial Services
Motilal Oswal Financial Services is a book-running lead manager and its private equity arm holds a stake through India Business Excellence Fund III, benefiting from the IPO.
Importance 50.0 Sentiment 40.0
cnt
India
The IPO is part of India's active primary market, contributing to the country's capital markets development.
Importance 40.0 Sentiment 30.0
priv
JM Financial
As a lead manager, JM Financial earns fees and enhances its reputation in the IPO market.
Importance 40.0 Sentiment 30.0
priv
Avendus Capital
As a lead manager, Avendus Capital earns fees and strengthens its investment banking portfolio.
Importance 40.0 Sentiment 30.0
stock
Nomura Holdings
Nomura Financial is a lead manager, earning fees and expanding its India presence.
Importance 40.0 Sentiment 30.0
priv
MUFG Intime India
As registrar, MUFG Intime India handles the IPO process, earning fees.
Importance 30.0 Sentiment 20.0
exch
Bombay Stock Exchange
The BSE will list Symbiotec's shares, adding to its listings and trading volumes.
Importance 30.0 Sentiment 20.0
exch
National Stock Exchange of India
The NSE will also list the shares, contributing to its market activity.
Importance 30.0 Sentiment 20.0
priv
InvAscent
InvAscent advises Rosewood Investments, benefiting from the successful exit.
Importance 30.0 Sentiment 20.0
curr
India — Indian rupee
The IPO is denominated in India — Indian rupees, reflecting the currency's role in the transaction.
Importance 20.0 Sentiment 10.0
priv
Concord Biotech
As a listed peer, Concord Biotech may see competitive dynamics but is not directly impacted.
Importance 20.0 Sentiment 10.0
+ 6 more entities View on Dashboard
Relationships
Motilal Oswal Financial Services related ↔ India
India related ↔ Avendus Capital
India related ↔ Nomura Holdings
India related ↔ MUFG Intime India
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.